The Effect of DA9301 on Tablet Computer-Induced Asthenopia

N

Namyi Gu

Status

Completed

Conditions

Asthenopia

Treatments

Dietary Supplement: Placebo
Dietary Supplement: DA9301 (Vaccinium uliginosum extract)

Study type

Interventional

Funder types

Other

Identifiers

NCT02641470
DA9301_01

Details and patient eligibility

About

Asthenopia or eye strain describes nonspecific symptoms of an eye when it is tired from intensive work. Vaccinium uliginosum is a flowering plant in the genus Vaccinium. This plant is native to cool temperature regions of the Northern Hemisphere. Considering its antioxidative ingredients, the extract of Vaccinium uliginosum is expected to play a significant role in treating various ocular pathologies. The investigators performed a randomized, case-controlled study in healthy subjects and investigated the protective effect of Vaccinium uliginosum extract (DA-9301) on tablet computer-induced asthenopia.

Enrollment

60 patients

Sex

All

Ages

20 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy subject aged 20 to 65 years with more than 2 hours of daily use of a smart phone or computer including a tablet and television

Exclusion criteria

  1. Ocular disease in either eye

    • Ocular surface disease
    • Best corrected visual acuity < 20/30
    • Intraocular pressure > 21 mmHg
    • Optical coherence tomography proven retinal nerve fiber defect
    • Significant cataract (lens opacities classification system III)
    • Significant entropion or ectropion
    • Significant tear drainage problem proved with fluorescein dye dilution test
  2. Soft or Hard contact lens use 3 or more days a week

  3. History of oral intake of health supplement designed to improve asthenopia within 4 weeks before participating this study

  4. Pregnant woman

  5. Systemic disease

    • Uncontrolled hypertension (systolic /diastolic blood pressure > 140/90mmHg)
    • Uncontrolled diabetes mellitus (fasting blood glucose level > 180mg/dL)
    • Rheumatoid arthritis
    • Malignant disease
    • Active hepatitis (type B and C)
    • Acute or chronic infectious disease
    • Renal disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

60 participants in 2 patient groups, including a placebo group

DA9301
Experimental group
Description:
Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
Treatment:
Dietary Supplement: DA9301 (Vaccinium uliginosum extract)
Placebo
Placebo Comparator group
Description:
Orally administration of placebo pills (1000 mg/day) for 4 weeks.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems